Scholars@Duke

Further ex vivo evidence supporting higher aspirin dosing in patients with coronary artery disease and diabetes.

Publication ,  Journal Article
Bliden, KP; Tantry, US; DiChiara, J; Gurbel, PA
Published in: Circ Cardiovasc Interv
April 1, 2011
Published version (DOI) Link to item

Duke Scholars

Paul Alfred Gurbel
Author Paul Alfred Gurbel Medicine, Clinical Pharmacology

Published In

Circ Cardiovasc Interv

DOI

10.1161/CIRCINTERVENTIONS.111.961847

EISSN

1941-7632

Publication Date

April 1, 2011

Volume

4

Issue

2

Start / End Page

118 / 120

Location

United States

Related Subject Headings

  • Platelet Aggregation Inhibitors
  • Platelet Aggregation
  • Humans
  • Dose-Response Relationship, Drug
  • Diabetic Angiopathies
  • Diabetes Mellitus, Type 2
  • Coronary Artery Disease
  • Cardiovascular System & Hematology
  • Aspirin
  • 3201 Cardiovascular medicine and haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Bliden, K. P., Tantry, U. S., DiChiara, J., & Gurbel, P. A. (2011). Further ex vivo evidence supporting higher aspirin dosing in patients with coronary artery disease and diabetes. Circ Cardiovasc Interv, 4(2), 118–120. https://doi.org/10.1161/CIRCINTERVENTIONS.111.961847
Bliden, Kevin P., Udaya S. Tantry, Joseph DiChiara, and Paul A. Gurbel. “Further ex vivo evidence supporting higher aspirin dosing in patients with coronary artery disease and diabetes.” Circ Cardiovasc Interv 4, no. 2 (April 1, 2011): 118–20. https://doi.org/10.1161/CIRCINTERVENTIONS.111.961847.
Bliden KP, Tantry US, DiChiara J, Gurbel PA. Further ex vivo evidence supporting higher aspirin dosing in patients with coronary artery disease and diabetes. Circ Cardiovasc Interv. 2011 Apr 1;4(2):118–20.
Bliden, Kevin P., et al. “Further ex vivo evidence supporting higher aspirin dosing in patients with coronary artery disease and diabetes.” Circ Cardiovasc Interv, vol. 4, no. 2, Apr. 2011, pp. 118–20. Pubmed, doi:10.1161/CIRCINTERVENTIONS.111.961847.
Bliden KP, Tantry US, DiChiara J, Gurbel PA. Further ex vivo evidence supporting higher aspirin dosing in patients with coronary artery disease and diabetes. Circ Cardiovasc Interv. 2011 Apr 1;4(2):118–120.

Published In

Circ Cardiovasc Interv

DOI

10.1161/CIRCINTERVENTIONS.111.961847

EISSN

1941-7632

Publication Date

April 1, 2011

Volume

4

Issue

2

Start / End Page

118 / 120

Location

United States

Related Subject Headings

  • Platelet Aggregation Inhibitors
  • Platelet Aggregation
  • Humans
  • Dose-Response Relationship, Drug
  • Diabetic Angiopathies
  • Diabetes Mellitus, Type 2
  • Coronary Artery Disease
  • Cardiovascular System & Hematology
  • Aspirin
  • 3201 Cardiovascular medicine and haematology